实用肝脏病杂志 ›› 2026, Vol. 29 ›› Issue (1): 37-40.doi: 10.3969/j.issn.1672-5069.2026.01.010

• 病毒性肝炎 • 上一篇    下一篇

更昔洛韦联合谷胱甘肽治疗儿童巨细胞病毒性肝炎疗效研究*

孙志伟, 陈小桥, 姜舒亚, 施科, 朱炜杰   

  1. 214002 江苏省无锡市 解放军联勤保障部队第904医院儿科(孙志伟,陈小桥,姜舒亚,施科);江南大学附属医院儿科(朱炜杰)
  • 收稿日期:2025-03-31 出版日期:2026-01-10 发布日期:2026-02-04
  • 作者简介:孙志伟,男,43岁,大学本科,副主任医师。 E-mail:sunzhiwei123131@sina.com
  • 基金资助:
    *江苏省自然科学基金资助项目(编号:BK20221422)

Clinical observation of intravenous administration of ganciclovir and glutathione in the treatment of children with cytomegalovirus-infected hepatitis

Sun Zhiwei, Chen Xiaoqiao, Jiang Shuya, et al   

  1. Department of Pediatrics, 904th Hospital, Joint Logistics Support Force, Wuxi 214002, Jiangsu Province, China
  • Received:2025-03-31 Online:2026-01-10 Published:2026-02-04

摘要: 目的 观察应用更昔洛韦联合谷胱甘肽治疗儿童巨细胞病毒(CMV)性肝炎的疗效。方法 2021年1月~2024年6月我院诊治的112例CMV肝炎儿童,给予更昔洛韦联合谷胱甘肽治疗2~3周。采用ELISA法检测血清白细胞介素-18(IL-18)、干扰素-γ(IFN-γ)和肿瘤坏死因子-α(TNF-α)水平,采用荧光定量PCR法检测血清CMV DNA载量。结果 在本组CMV肝炎儿童中,轻症74例和重症38例;经过治疗,重症组血清ALT和TBIL水平由(244.7±25.9)U/L和(167.5±22.3)μmol/L分别降至(45.5±11.0)U/L和(31.2±5.8)μmol/L,轻症组患儿肝功能指标均恢复正常; 重症组血清IL-18和TNF-α水平由(74.8±27.9)pg/L和(41.0±10.2)pg/ml分别降至(42.2±12.3)pg/L和(35.3±7.9)pg/ml(P<0.05),轻症组则分别由(56.4±17.4)pg/L和(39.4±6.9)pg/ml降至(35.1±10.7)pg/L和(28.7±5.8)pg/ml(P<0.05);轻症组血清CMV DNA转阴时间为(7.5±2.2)d,显著短于重症组【(13.0±5.5)d,P<0.05】;本组轻症CMV患儿全部痊愈,1例(2.6%)重症患儿因肝衰竭并发肺部严重感染死亡。结论 应用更昔洛韦联合谷胱甘肽治疗儿童巨细胞病毒(CMV)性肝炎疗效肯定,对于重症患儿需加强监护,防止病情发展。

关键词: 巨细胞病毒性肝炎, 更昔洛韦, 谷胱甘肽, 治疗

Abstract: Objective The aim of this study was to investigate the efficacy of intravenous administration of ganciclovir and glutathione in the treatment of children with cytomegalovirus (CMV)-infected hepatitis. Methods A consecutive 112 children with CMV hepatitis were encountered in our hospital between January 2021 and June 2024, and all children received intravenous administration of ganciclovir and glutathione for 2 to 3 weeks. Serum interleukin-18 (IL-18), interferon-γ(IFN-γ) and tumor necrosis factor-α(TNF-α) levels were assayed by ELISA, and serum CMV DNA loads were determined by PCR. Results Of our series, the children with CMV hepatitis were found mild hepatitis (MH) in 74 cases and severe hepatitis (SH) in 38 cases; after treatment, serum ALT and total serum bilirubin levels in children with SH decreased from (244.7±25.9)U/L and (167.5±22.3)μmol/L to (45.5±11.0)U/L and (31.2±5.8)μmol/L, respectively, and serum biochemical parameters returned to normal in children with MH; serum IL-18 and TNF-α levels in children with SH decreased from (74.8±27.9)pg/L and (41.0±10.2)pg/ml to (42.2±12.3)pg/L and (35.3±7.9)pg/ml(P<0.05), respectively, and they reduced from (56.4±17.4)pg/L and (39.4±6.9)pg/ml to (35.1±10.7)pg/L and (28.7±5.8)pg/ml(P<0.05) in those with MH; serum CMV DNA load returned to negative in (7.5±2.2)d in children with MH, much shorter than [(13.0±5.5)d, P<0.05] in those with SH; all patients but one (2.6%)who died of liver failure with complicated pneumonia with CMV-infected hepatitis recovered in our series. Conclusion Intravenous administration of ganciclovir and glutathione in the treatment of children with CMV-infected hepatitis is efficacious, and the pediatrics should take care of those with SH and deal with any complications in time.

Key words: Cytomegalovirus hepatitis, Ganciclovir, Glutathione, Therapy